Business
Biocon Biologics and Civica Expand Partnership and Launch Private-Label Insulin Glargine to Broaden U.S. Diabetes Treatment Options
Biocon Biologics Ltd. (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd. (BSE code: 532523, NSE: BIOCON), today announced expansion of its strategic collaboration with Civica, Inc. (Civica) to include a new Insulin Glargine medicine that will benefit patients in the United States by increasing supply of high-quality affordable insulins.
About this update from Biocon Limited
[{"type":"text","content":"Additional treatment options for the 38.4 million U.S. patients living with diabetes","length":84,"tagName":"p","attribs":{}},{"type":"text","content":"BRIDGEWATER, N.J. and BENGALURU, India, Oct. 16, 2025 /PRNewswire/ -- Biocon Biologics Ltd. (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd. (BSE code: 532523, NSE: BIOCON), today announced expansion of its strategic collaboration with Civica, Inc. (Civica) to include a new Insulin Glargine medicine that will benefit patients in the United States by increasing supply of high-quality affordable insulins.","length":450,"tagName":"p"},{"type":"image","alt":"Biocon Biologics (PRNewsfoto/Biocon Biologics)","displaySize":"","headline":null,"caption":"Biocon Biologics (PRNewsfoto/Biocon Biologics)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":250,"url":"https://media.zenfs.com/en/prnewswire.com/f52c945188fde03caec2c4e41e57e558"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/dHzfawpfy0cFqQUi6PoEtQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTQ0MTtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/f52c945188fde03caec2c4e41e57e558","width":400,"height":250}},"href":"https://mma.prnewswire.com/media/2775049/biocon_biologics_logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"The multi-year transformational agreement between Biocon Biologics and Civica creates an exclusive distributorship arrangement where Biocon Biologics will manufacture and supply Insulin Glargine medicine to Civica, and Civica will commercialize under Biocon Biologics' existing marketing approval (a private label agreement). Civica will distribute, promote, and sell the medicine in the United States under a separate Civica label and trade dress, and in California, the product will carry the CalRx brand. Biocon Biologics will continue to directly commercialize Biocon Biologics' own Insulin Glargine-yfgn medicine, which was approved by the U.S. Food and Drug Administration (FDA) in July 2021 as the first interchangeable biosimilar.","length":746,"tagName":"p"},{"type":"text","content":" Shreehas Tambe, CEO & Managing Director, Biocon Biologics Ltd, said : " Biocon Biologics is committed to expanding access to affordable, high-quality insulins in the U.S. and globally. By extending our collaboration with ...